Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. announced that PharmAla has completed the first sale of a quantity of Mindset's cGMP (i.e. pharmaceutical grade) psilocybin under their exclusive sales agreement. The psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX listed Little Green Pharma. Reset recently received human research ethics committee approval for a clinical trial investigating psilocybin assisted psychotherapy protocols for patients with treatment resistant major depressive disorder.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.185 CAD | -2.63% | 0.00% | +32.14% |
May. 03 | PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy | MT |
Apr. 23 | Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla | CI |
1st Jan change | Capi. | |
---|---|---|
+32.14% | 12.08M | |
+10.46% | 115B | |
+12.22% | 106B | |
-5.92% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.60% | 17.56B | |
-40.50% | 17.32B | |
+6.48% | 14.03B | |
+30.33% | 12.13B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. Complete First Sale of Pharmaceutical Grade Psilocybin into Growing Australian Market Via Sales Partnership